Q32 Bio (QTTB) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.44
- Estimate
- -$0.54
- Surprise
- +18.8%
- Score today
- 6.9/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Q32 Bio (QTTB) reported a narrower loss than forecast — diluted EPS of -$0.44 against the -$0.54 estimate (a 18.8% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates QTTB Strong Buy at 6.9/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +18.8% surprise compares with a +180.4% four-quarter average.
What supports the rating
- Strong earnings beat streak (4/4)
- High-quality business
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $15.81
- Entry target
- $15.80
- Price target
- $36.34
- Stop
- $14.69
- Upside to target
- +129.9%
- Reward-to-risk
- 11.6:1
Model outputs from TrendMatrix’s engine as of 2026-08-21 — shown for context, not personalized investment advice.
QTTB at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $472.1M
- P/E (fwd)
- -15.5
- P/E (ttm)
- 5.1
- 52-week range
- $1.62–$23.57
- Off 52-week high
- 32.9%
- RSI (14)
- 56
- Volume vs avg
- 0.30×
- Score today
- 6.9/10